194 / 1084
Summary
• Incidence of adenocarcinoma is increasing
• Overall prognosis is dismal (despite some advances), mainly due to:
– locally advanced disease (we diagnose too late)
– early lymph nodes metastasis (intense network of lymph vessels)
– no well defined subtypes
– treatment options are still insufficient (personalized: Herceptin only)
Institute of Pathology | Alexander Quaas
Gastrointestinal Cancer Group Cologne (GCGC)
• No EBV and MSI subtypes
• PDL1-checkpoint-inhibition less effective?
• HER2/neu still the only personalized treatment option
• >7 regional lymph nodes
• Standardized work flow in pathology embedding of whole tumor bed
• Regression scores after neoadjuvant treatment